BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang L, Ping L, Yan H, Yang X, He Q, Xu Z, Luo P. Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert Opin Drug Metab Toxicol 2020;16:823-35. [PMID: 32597258 DOI: 10.1080/17425255.2020.1787986] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Cui C, Ren X, Dong X, Cui W. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021. Front Cardiovasc Med 2022;9:988013. [PMID: 36312283 DOI: 10.3389/fcvm.2022.988013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Syukri A, Budu, Hatta M, Amir M, Rohman MS, Mappangara I, Kaelan C, Wahyuni S, Bukhari A, Junita AR, Primaguna MR, Dwiyanti R, Febrianti A. Doxorubicin induced immune abnormalities and inflammatory responses via HMGB1, HIF1-α and VEGF pathway in progressive of cardiovascular damage. Annals of Medicine and Surgery 2022;76:103501. [DOI: 10.1016/j.amsu.2022.103501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Feng Y, Li Y, Yang X, Han L, Wang L, Gao S, Yin R, Wang X, Li J, Liu M, Li B. Direct evidence of VEGF-mediated neuroregulation and afferent explanation of blood pressure dysregulation during angiogenic therapy. Frigid Zone Medicine 2021;1:119-126. [DOI: 10.2478/fzm-2021-0015] [Reference Citation Analysis]
4 Enokida T, Tahara M. Management of VEGFR-Targeted TKI for Thyroid Cancer. Cancers (Basel) 2021;13:5536. [PMID: 34771698 DOI: 10.3390/cancers13215536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]